BIOTON S.A. (BIO.WA)
PLN 3.66
(0.55%)
PLN 3.66
(0.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 43.89 Million PLN | -38.32% |
| 2022 | 58.55 Million PLN | 21.45% |
| 2021 | 45.09 Million PLN | -47.72% |
| 2020 | 76.26 Million PLN | 311.17% |
| 2019 | -124.52 Million PLN | -190.26% |
| 2018 | 52.69 Million PLN | -132.77% |
| 2017 | 22.16 Million PLN | 79.72% |
| 2016 | 21.41 Million PLN | -65.64% |
| 2015 | -495.7 Million PLN | -1.58% |
| 2014 | 67.05 Million PLN | 75.27% |
| 2013 | 38.25 Million PLN | -53.79% |
| 2012 | 94.38 Million PLN | 516.33% |
| 2011 | -12.22 Million PLN | -90.1% |
| 2010 | 125.97 Million PLN | 127.79% |
| 2009 | -507.91 Million PLN | -811.99% |
| 2008 | -53.53 Million PLN | -141.86% |
| 2007 | 47.92 Million PLN | -4.7% |
| 2006 | 124.35 Million PLN | 159.38% |
| 2005 | 51.73 Million PLN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 6.67 Million PLN | 57.76% |
| 2024 Q1 | 3.58 Million PLN | -74.36% |
| 2023 Q3 | 3.87 Million PLN | -75.26% |
| 2023 Q2 | 15.66 Million PLN | 38.02% |
| 2023 Q1 | 11.34 Million PLN | 3.2% |
| 2023 FY | - PLN | -38.32% |
| 2023 Q4 | 1.42 Million PLN | -63.2% |
| 2022 Q2 | 11.04 Million PLN | 27.4% |
| 2022 Q3 | 12.35 Million PLN | 11.85% |
| 2022 Q4 | 10.99 Million PLN | -11.01% |
| 2022 FY | - PLN | 21.45% |
| 2022 Q1 | 8.67 Million PLN | -8.9% |
| 2021 FY | - PLN | -47.72% |
| 2021 Q1 | 7.94 Million PLN | -73.72% |
| 2021 Q4 | 9.52 Million PLN | -36.58% |
| 2021 Q2 | 11.69 Million PLN | 47.16% |
| 2021 Q3 | 15.01 Million PLN | 28.35% |
| 2020 Q4 | 30.23 Million PLN | 155.2% |
| 2020 FY | - PLN | 311.17% |
| 2020 Q1 | 22.11 Million PLN | 163.76% |
| 2020 Q2 | 11.26 Million PLN | -49.04% |
| 2020 Q3 | 11.84 Million PLN | 5.15% |
| 2019 Q1 | 14.32 Million PLN | 132.61% |
| 2019 Q2 | -86.4 Million PLN | -703.19% |
| 2019 Q3 | 5.77 Million PLN | 106.69% |
| 2019 Q4 | -34.68 Million PLN | -700.16% |
| 2019 FY | - PLN | -190.26% |
| 2018 Q3 | 4.36 Million PLN | -94.34% |
| 2018 Q1 | 14.82 Million PLN | 92.29% |
| 2018 FY | - PLN | -132.77% |
| 2018 Q2 | 77.18 Million PLN | 420.7% |
| 2018 Q4 | -43.91 Million PLN | -1105.93% |
| 2017 Q4 | 7.7 Million PLN | -24.54% |
| 2017 FY | - PLN | 79.72% |
| 2017 Q3 | 10.21 Million PLN | -26.98% |
| 2017 Q2 | 13.99 Million PLN | 99.61% |
| 2017 Q1 | 7 Million PLN | 165.11% |
| 2016 Q4 | -10.76 Million PLN | -209.27% |
| 2016 FY | - PLN | -65.64% |
| 2016 Q1 | 14.11 Million PLN | 102.54% |
| 2016 Q2 | 8.2 Million PLN | -41.89% |
| 2016 Q3 | 9.85 Million PLN | 20.1% |
| 2015 FY | - PLN | -1.58% |
| 2015 Q4 | -555.3 Million PLN | -2168.95% |
| 2015 Q3 | 26.84 Million PLN | 92.71% |
| 2015 Q2 | 13.92 Million PLN | -16.39% |
| 2015 Q1 | 16.65 Million PLN | -13.1% |
| 2014 FY | - PLN | 75.27% |
| 2014 Q3 | 18.88 Million PLN | -15.22% |
| 2014 Q2 | 22.27 Million PLN | 94.0% |
| 2014 Q4 | 19.17 Million PLN | 1.53% |
| 2014 Q1 | 11.48 Million PLN | 36.33% |
| 2013 FY | - PLN | -53.79% |
| 2013 Q4 | 8.42 Million PLN | -23.78% |
| 2013 Q2 | 14.82 Million PLN | -20.01% |
| 2013 Q1 | 18.53 Million PLN | 880.94% |
| 2013 Q3 | 11.04 Million PLN | -25.46% |
| 2012 Q2 | -11.22 Million PLN | -112.1% |
| 2012 Q1 | 92.77 Million PLN | 2180.12% |
| 2012 FY | - PLN | 516.33% |
| 2012 Q3 | 10.93 Million PLN | 197.45% |
| 2012 Q4 | 1.88 Million PLN | -82.73% |
| 2011 Q3 | 25.13 Million PLN | 465.64% |
| 2011 FY | - PLN | -90.1% |
| 2011 Q1 | -6.04 Million PLN | -105.1% |
| 2011 Q2 | -6.87 Million PLN | -13.73% |
| 2011 Q4 | 4.06 Million PLN | -83.81% |
| 2010 Q1 | 236 Thousand PLN | 100.05% |
| 2010 Q3 | 9.12 Million PLN | -46.2% |
| 2010 FY | - PLN | 127.79% |
| 2010 Q4 | 118.42 Million PLN | 1197.94% |
| 2010 Q2 | 16.96 Million PLN | 7086.44% |
| 2009 Q3 | 28.24 Million PLN | 195.54% |
| 2009 Q4 | -491.58 Million PLN | -1840.45% |
| 2009 Q2 | -29.56 Million PLN | -192.83% |
| 2009 Q1 | 31.84 Million PLN | 0.0% |
| 2009 FY | - PLN | -811.99% |
| 2008 FY | - PLN | -141.86% |
| 2007 FY | - PLN | -4.7% |
| 2006 FY | - PLN | 159.38% |
| 2005 FY | - PLN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioceltix S.A. | -13.22 Million PLN | 431.94% |
| Captor Therapeutics Spolka Akcyjna | -64.76 Million PLN | 167.78% |
| Mabion S.A. | 58.31 Million PLN | 24.722% |
| Molecure S.A. | -25.5 Million PLN | 272.106% |
| NanoGroup S.A. | -7.87 Million PLN | 657.758% |
| Pharmena S.A. | 33.78 Million PLN | -29.95% |
| Poltreg S.A. | -11.65 Million PLN | 476.507% |
| Pure Biologics Spólka Akcyjna | -26.07 Million PLN | 268.336% |
| Ryvu Therapeutics S.A. | -81.04 Million PLN | 154.164% |
| Synthaverse S.A. | 15.34 Million PLN | -186.048% |
| Urteste S.A. | -5.73 Million PLN | 865.957% |